Table 3

CrEL concentration-dependent blood:plasma ratio and unbound paclitaxel fraction in plasma of a patienta

Time (h)bCrEL (%)Blood:plasma ratioUnbound fraction
0.500.0391.020.076
1.00.1220.7950.057
1.50.1570.8510.038
2.00.2150.7490.028
2.50.3000.7370.022
3.00.3350.6230.016
  • a Paclitaxel was administered as an i.v. infusion over a 3-h period at an absolute dose of 256 mg to a single female with advanced ovarian cancer.

  • b Sample collection time point after the start of a 3-h i.v. infusion of paclitaxel.